Reducing the development of antibiotic resistance in critical care units

Current Pharmaceutical Biotechnology

Volumn 12, Issue 12, 2011, Pages 2062-2069

  Deege, Marjolein P D ^a   Paterson, David L ^a,b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Antibiotic resistance; Antimicrobial stewardship; Critical care unit; ESBL; MRSA

Indexed keywords

AMINOGLYCOSIDE; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; CARBAPENEM DERIVATIVE; CEFPIROME; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; DAPTOMYCIN; DORIPENEM; ENOXACIN; IMIPENEM; LINEZOLID; MEROPENEM; MOXIFLOXACIN; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLONE DERIVATIVE; TEICOPLANIN; VANCOMYCIN;

ACINETOBACTER; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL ENDOCARDITIS; ENTEROBACTERIACEAE; HAND WASHING; HOSPITAL INFECTION; HUMAN; INFECTION CONTROL; INTENSIVE CARE; INTENSIVE CARE UNIT; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PATIENT CARE; PRACTICE GUIDELINE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; STAPHYLOCOCCUS INFECTION; STENOTROPHOMONAS MALTOPHILIA; VANCOMYCIN RESISTANT ENTEROCOCCUS; VENTILATOR ASSOCIATED PNEUMONIA;

DECONTAMINATION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; HANDWASHING; HUMANS; INFECTION CONTROL; INTENSIVE CARE UNITS;

ACINETOBACTER; ENTEROBACTERIACEAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NEGIBACTERIA; POSIBACTERIA; PSEUDOMONAS AERUGINOSA; STENOTROPHOMONAS MALTOPHILIA;

EID: 84855217896     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920111798808301     Document Type: Article

References (83)

1. Watanabe, M.; Iyobe, S.; Inoue, M.; Mitsuhashi, S. Transferable imipenem resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother, 1991, 35(1), 147-51.
2. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control, 2004, 32(8), 470-85.
3. EARSS annual report. http://www.rivm.nl/earss/Images/EARSS%202008_final_tcm61-65020.pdf (Accessed January 15, 2010).
4. Cassone, M.; Campanile, F.; Pantosti, A.; Venditti, M.; Stefani, S. Identification of a variant Rome clone of methicillin-resistant Staphylococcus aureus with decreased susceptibility to vancomycin, responsible for an outbreak in an intensive care unit. Microb. Drug Resist., 2004, 10(1), 43-49.
5. Ploy, M.C.; Francois, B.; Mounier, M.; Vignon, P.; Denis, F. Nasal carriage of vancomycin-intermediate Staphylococcus aureus among intensive care unit staff. Clin. Infect. Dis., 2001, 33(11), 1951.
6. de Lassence, A.; Hidri, N.; Timsit, J.F.; Joly-Guillou, M.L.; Thiery, G.; Boyer, A.; Lable, P.; Blivet, A.; Kalinowski, H.; Martin, Y.; Lajonchere, J.P.; Dreyfuss, D. Control and outcome of a large outbreak of colonization and infection with glycopeptideintermediate Staphylococcus aureus in an intensive care unit. Clin. Infect. Dis., 2006, 42(2), 170-178.
7. Chua, K.; Howden, B.P. Treating Gram-positive infections: vancomycin update and the whys, wherefores and evidence base for continuous infusion of anti-Gram-positive antibiotics. Curr. Opin. Infect. Dis., 2009, 22(6), 525-534.
8. Tsiodras, S.; Gold, H.S.; Sakoulas, G.; Eliopoulos, G.M.; Wennersten, C.; Venkataraman, L.; Moellering, R.C.; Ferraro, M.J. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet, 2001, 358(9277), 207-208.
9. Ross, J.E.; Anderegg, T.R.; Sader, H.S.; Fritsche, T.R.; Jones, R.N. Trends in linezolid susceptibility patterns in 2002: report from the worldwide Zyvox Annual Appraisal of Potency and Spectrum Program. Diagn. Microbiol. Infect. Dis., 2005, 52(1), 53-58.
10. Roberts, S.M.; Freeman, A.F.; Harrington, S.M.; Holland, S.M.; Murray, P.R.; Zelazny, A.M. Linezolid-resistant Staphylococcus aureus in two pediatric patients receiving low-dose linezolid therapy. Pediatr. Infect. Dis. J., 2006, 25(6), 562-564.
11. Hentschke, M.; Saager, B.; Horstkotte, M. A.; Scherpe, S.; Wolters, M.; Kabisch, H.; Grosse, R.; Heisig, P.; Aepfelbacher, M.; Rohde, H. Emergence of linezolid resistance in a methicillin resistant Staphylococcus aureus strain. Infection, 2008, 36(1), 85-87.
12. Yoshida, K.; Shoji, H.; Hanaki, H.; Yanagisawa, C.; Ikeda- Dantsuji, Y.; Fukuchi, K.; Adachi, M.; Niki, Y. Linezolid-resistant methicillin-resistant Staphylococcus aureus isolated after longterm, repeated use of linezolid. J. Infect. Chemother., 2009, 15(6), 417-419.
13. Paterson, D.L.; Pasculle, A.W.; McCurry, K. Linezolid: the first oxazolidinone antimicrobial. Ann. Intern. Med., 2003, 139(10), 863-864.
14. Hayden, M.K.; Rezai, K.; Hayes, R.A.; Lolans, K.; Quinn, J.P.; Weinstein, R.A. Development of Daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus. J. Clin. Microbiol., 2005, 43(10), 5285-5287.
15. Hirschwerk, D.; Ginocchio, C.C.; Bythrow, M.; Condon, S. Diminished susceptibility to daptomycin accompanied by clinical failure in a patient with methicillin-resistant Staphylococcus aureus bacteremia. Infect. Control Hosp. Epidemiol., 2006, 27(3), 315-317.
16. Mangili, A.; Bica, I.; Snydman, D. R.; Hamer, D.H. Daptomycinresistant, methicillin-resistant Staphylococcus aureus bacteremia. Clin. Infect. Dis., 2005, 40(7), 1058-1060.
17. Marty, F.M.; Yeh, W.W.; Wennersten, C.B.; Venkataraman, L.; Albano, E.; Alyea, E. P.; Gold, H.S.; Baden, L.R.; Pillai, S.K. Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis. J. Clin. Microbiol., 2006, 44(2), 595-597.
18. Skiest, D.J. Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin. J. Clin. Microbiol., 2006, 44(2), 655-656.
19. Vikram, H.R.; Havill, N.L.; Koeth, L.M.; Boyce, J.M. Clinical progression of methicillin-resistant Staphylococcus aureus vertebral osteomyelitis associated with reduced susceptibility to daptomycin. J. Clin. Microbiol., 2005, 43(10), 5384-5387.
20. Mariani, P.G.; Sader, H.S.; Jones, R.N. Development of decreased susceptibility to daptomycin and vancomycin in a Staphylococcus aureus strain during prolonged therapy. J. Antimicrob. Chemother., 2006, 58(2), 481-483.
21. Sakoulas, G.; Rose, W.; Rybak, M.J.; Pillai, S.; Alder, J.; Moellering, R.C., Jr.; Eliopoulos, G.M. Evaluation of endocarditis caused by methicillin-susceptible Staphylococcus aureus developing nonsusceptibility to daptomycin. J. Clin. Microbiol., 2008, 46(1), 220-224.
22. Potoski, B.A.; Adams, J.; Clarke, L.; Shutt, K.; Linden, P.K.; Baxter, C.; Pasculle, A. W.; Capitano, B.; Peleg, A.Y.; Szabo, D.; Paterson, D.L. Epidemiological profile of linezolid-resistant coagulase-negative staphylococci. Clin. Infect. Dis., 2006, 43(2), 165-171.
23. Willems, R.J.; Top, J.; van Santen, M.; Robinson, D.A.; Coque, T.M.; Baquero, F.; Grundmann, H.; Bonten, M.J. Global spread of vancomycin-resistant Enterococcus faecium from distinct nosocomial genetic complex. Emerg. Infect. Dis., 2005, 11(6), 821-828.
24. Morrison, A.J., Jr.; Wenzel, R.P. Epidemiology of infections due to Pseudomonas aeruginosa. Rev. Infect. Dis., 1984, 6(Suppl 3), S627-642.
25. Peleg, A Y.; Seifert, H.; Paterson, D.L. Acinetobacter baumannii: emergence of a successful pathogen. Clin. Microbiol. Rev., 2008, 21(3), 538-582.
26. Poirel, L.; Nordmann, P. Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. Clin. Microbiol. Infect., 2006, 12(9), 826-836.
27. McDonald, L.C. Trends in antimicrobial resistance in health careassociated pathogens and effect on treatment. Clin. Infect. Dis., 2006, 42(Suppl 2), S65-71.
28. Turner, P.J. MYSTIC Europe 2007: activity of meropenem and other broad-spectrum agents against nosocomial isolates. Diagn. Microbiol. Infect. Dis., 2009, 63(2), 217-222.
29. Lytsy, B.; Sandegren, L.; Tano, E.; Torell, E.; Andersson, D.I.; Melhus, A. The first major extended-spectrum beta-lactamase outbreak in Scandinavia was caused by clonal spread of a multiresistant Klebsiella pneumoniae producing CTX-M-15. APMIS, 2008, 116(4), 302-308.
30. Sader, H.S.; Jones, R.N. Antimicrobial susceptibility of uncommonly isolated non-enteric Gram-negative bacilli. Int. J. Antimicrob. Agents, 2005, 25(2), 95-109.
31. Gales, A.C.; Jones, R.N.; Forward, K.R.; Linares, J.; Sader, H.S.; Verhoef, J. Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997-1999). Clin. Infect. Dis., 2001, 32(Suppl 2), S104-113.
32. Muto, C.A.; Jernigan, J.A.; Ostrowsky, B.E.; Richet, H.M.; Jarvis, W.R.; Boyce, J. M.; Farr, B.M. SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and enterococcus. Infect. Control Hosp. Epidemiol., 2003, 24(5), 362-386.
33. Siegel, J.D.; Rhinehart, E.; Jackson, M.; Chiarello, L. Management of multidrug-resistant organisms in health care settings, 2006. Am. J. Infect. Control., 2007, 35(10 Suppl 2), S165-193.
34. Perencevich, E.N.; Fisman, D.N.; Lipsitch, M.; Harris, A D.; Morris, J.G., Jr.; Smith, D.L. Projected benefits of active surveillance for vancomycin-resistant enterococci in intensive care units. Clin. Infect. Dis., 2004, 38(8), 1108-1115.
35. Sebille, V.; Chevret, S.; Valleron, A.J. Modeling the spread of resistant nosocomial pathogens in an intensive-care unit. Infect. Control Hosp. Epidemiol., 1997, 18(2), 84-92.
36. Bootsma, M.C.; Diekmann, O.; Bonten, M.J. Controlling methicillin-resistant Staphylococcus aureus: quantifying the effects of interventions and rapid diagnostic testing. Proc. Natl. Acad. Sci. USA, 2006, 103(14), 5620-5625.
37. Austin, D.J.; Bonten, M.J.; Weinstein, R.A.; Slaughter, S.; Anderson, R.M. Vancomycin-resistant enterococci in intensivecare hospital settings: transmission dynamics, persistence, and the impact of infection control programs. Proc. Natl. Acad. Sci. USA, 1999, 96(12), 6908-6913.
38. Kluytmans-Vandenbergh, M.F.; Kluytmans, J.A.; Voss, A. Dutch guideline for preventing nosocomial transmission of highly resistant microorganisms (HRMO). Infection, 2005, 33(5-6), 309-313.
39. Vos, M.C.; Behrendt, M.D.; Melles, D.C.; Mollema, F.P.; de Groot, W.; Parlevliet, G.; Ott, A.; Horst-Kreft, D.; van Belkum, A.; Verbrugh, H.A. 5 years of experience implementing a methicillinresistant Staphylococcus aureus search and destroy policy at the largest university medical center in the Netherlands. Infect. Control. Hosp. Epidemiol., 2009, 30(10), 977-984.
40. Cooper, B.S.; Stone, S.P.; Kibbler, C.C.; Cookson, B.D.; Roberts, J.A.; Medley, G.F.; Duckworth, G.; Lai, R.; Ebrahim, S. Isolation measures in the hospital management of methicillin resistant Staphylococcus aureus (MRSA): systematic review of the literature. BMJ, 2004, 329(7465), 533.
41. WHO WHO Guidelines on Hand Hygiene in Health Care. http://whqlibdoc.who.int/publications/2009/9789241597906_eng.pdf (accessed Febuary 17, 2010).
42. Pittet, D.; Allegranzi, B.; Sax, H.; Dharan, S.; Pessoa-Silva, C.L.; Donaldson, L.; Boyce, J.M. Evidence-based model for hand transmission during patient care and the role of improved practices. Lancet Infect. Dis., 2006, 6(10), 641-652.
43. Boyce, J.M.; Potter-Bynoe, G.; Chenevert, C.; King, T. Environmental contamination due to methicillin-resistant Staphylococcus aureus: possible infection control implications. Infect. Control. Hosp. Epidemiol., 1997, 18(9), 622-627.
44. Hayden, M.K.; Blom, D.W.; Lyle, E.A.; Moore, C.G.; Weinstein, R.A. Risk of hand or glove contamination after contact with patients colonized with vancomycin-resistant enterococcus or the colonized patients' environment. Infect. Control Hosp. Epidemiol., 2008, 29(2), 149-154.
45. Ray, A.J.; Hoyen, C.K.; Taub, T.F.; Eckstein, E.C.; Donskey, C.J. Nosocomial transmission of vancomycin-resistant enterococci from surfaces. JAMA, 2002, 287(11), 1400-1401.
46. Bhalla, A.; Pultz, N.J.; Gries, D.M.; Ray, A.J.; Eckstein, E.C.; Aron, D.C.; Donskey, C.J. Acquisition of nosocomial pathogens on hands after contact with environmental surfaces near hospitalized patients. Infect. Control. Hosp. Epidemiol., 2004, 25(2), 164-167.
47. Olsen, R.J.; Lynch, P.; Coyle, M.B.; Cummings, J.; Bokete, T.; Stamm, W.E. Examination gloves as barriers to hand contamination in clinical practice. JAMA, 1993, 270(3), 350-353.
48. Tenorio, A.R.; Badri, S.M.; Sahgal, N.B.; Hota, B.; Matushek, M.; Hayden, M.K.; Trenholme, G.M.; Weinstein, R.A. Effectiveness of gloves in the prevention of hand carriage of vancomycin-resistant enterococcus species by health care workers after patient care. Clin. Infect. Dis., 2001, 32(5), 826-829.
49. Wertheim, H.F.; Melles, D.C.; Vos, M.C.; van Leeuwen, W.; van Belkum, A.; Verbrugh, H.A.; Nouwen, J.L. The role of nasal carriage in Staphylococcus aureus infections. Lancet Infect. Dis., 2005, 5(12), 751-762.
50. van Rijen, M.; Bonten, M.; Wenzel, R.; Kluytmans, J. Mupirocin ointment for preventing Staphylococcus aureus infections in nasal carriers. Cochrane Database Syst. Rev., 2008, (4), CD006216.
51. Ammerlaan, H.S.; Kluytmans, J.A.; Wertheim, H.F.; Nouwen, J.L.; Bonten, M.J. Eradication of methicillin-resistant Staphylococcus aureus carriage: a systematic review. Clin. Infect. Dis., 2009, 48(7), 922-930.
52. Deshpande, L.M.; Fix, A.M.; Pfaller, M.A.; Jones, R.N. Emerging elevated mupirocin resistance rates among staphylococcal isolates in the SENTRY Antimicrobial Surveillance Program (2000): correlations of results from disk diffusion, Etest and reference dilution methods. Diagn. Microbiol. Infect. Dis., 2002, 42(4), 283-290.
53. Vivoni, A.M.; Santos, K.R.; de-Oliveira, M.P.; GiambiagideMarval, M.; Ferreira, A. L.; Riley, L.W.; Moreira, B.M. Mupirocin for controlling methicillin-resistant Staphylococcus aureus: lessons from a decade of use at a university hospital. Infect. Control Hosp. Epidemiol., 2005, 26(7), 662-627.
54. Bode, L.G.; Kluytmans, J.A.; Wertheim, H.F.; Bogaers, D.; Vandenbroucke-Grauls, C.M.; Roosendaal, R.; Troelstra, A.; Box, A.T.; Voss, A.; van der Tweel, I.; van Belkum, A.; Verbrugh, H.A.; Vos, M.C. Preventing surgical-site infections in nasal carriers of Staphylococcus aureus. N. Engl. J. Med., 2010, 362(1), 9-17.
55. de Jonge, E.; Schultz, M.J.; Spanjaard, L.; Bossuyt, P.M.; Vroom, M.B.; Dankert, J.; Kesecioglu, J. Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial. Lancet, 2003, 362(9389), 1011-1016.
56. D'Amico, R.; Pifferi, S.; Leonetti, C.; Torri, V.; Tinazzi, A.; Liberati, A. Effectiveness of antibiotic prophylaxis in critically ill adult patients: systematic review of randomised controlled trials. BMJ, 1998, 316(7140), 1275-1285.
57. Pugin, J.; Auckenthaler, R.; Lew, D.P.; Suter, P.M. Oropharyngeal decontamination decreases incidence of ventilator-associated pneumonia. A randomized, placebo-controlled, double-blind clinical trial. JAMA, 1991, 265(20), 2704-2710.
58. Bergmans, D.C.; Bonten, M.J.; Gaillard, C.A.; Paling, J.C.; van der Geest, S.; van Tiel, F.H.; Beysens, A.J.; de Leeuw, P.W.; Stobberingh, E.E. Prevention of ventilator-associated pneumonia by oral decontamination: a prospective, randomized, double-blind, placebo-controlled study. Am. J. Respir. Crit. Care Med., 2001, 164(3), 382-388.
59. de Smet, A.M.; Kluytmans, J.A.; Cooper, B.S.; Mascini, E.M.; Benus, R.F.; van der Werf, T.S.; van der Hoeven, J.G.; Pickkers, P.; Bogaers-Hofman, D.; van der Meer, N.J.; Bernards, A.T.; Kuijper, E.J.; Joore, J.C.; Leverstein-van Hall, M.A.; Bindels, A. J.; Jansz, A.R.; Wesselink, R.M.; de Jongh, B.M.; Dennesen, P.J.; van Asselt, G.J.; te Velde, L.F.; Frenay, I.H.; Kaasjager, K.; Bosch, F.H.; van Iterson, M.; Thijsen, S.F.; Kluge, G.H.; Pauw, W.; de Vries, J.W.; Kaan, J.A.; Arends, J.P.; Aarts, L.P.; Sturm, P.D.; Harinck, H.I.; Voss, A.; Uijtendaal, E.V.; Blok, H.E.; Thieme Groen, E.S.; Pouw, M.E.; Kalkman, C.J.; Bonten, M. J. Decontamination of the digestive tract and oropharynx in ICU patients. N. Engl. J. Med., 2009, 360(1), 20-31.
60. Oostdijk, E.A.; De Smet, A.M.; Blok, H E.; Thieme Groen, E.S.; van Asselt, G.J.; Benus, R.F.; Bernards, S.A.; Frenay, I.H.; Jansz, A.R.; de Jongh, B.M.; Kaan, J.A.; Leverstein-van Hall, M.A.; Mascini, E.M.; Pauw, W.; Sturm, P.D.; Thijsen, S.F.; Kluytmans, J.A.; Bonten, M.J. Ecological effects of selective decontamination on resistant gram-negative bacterial colonization. Am. J. Respir. Crit. Care Med., 2009, 181(5), 452-457.
61. Goodman, E.R.; Platt, R.; Bass, R.; Onderdonk, A.B.; Yokoe, D.S.; Huang, S.S. Impact of an environmental cleaning intervention on the presence of methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci on surfaces in intensive care unit rooms. Infect. Control Hosp. Epidemiol., 2008, 29(7), 593-599.
62. Dancer, S.J.; White, L.F.; Lamb, J.; Girvan, E.K.; Robertson, C. Measuring the effect of enhanced cleaning in a UK hospital: a prospective cross-over study. BMC Med., 2009, 7, 28.
63. Eckstein, B.C.; Adams, D.A.; Eckstein, E.C.; Rao, A.; Sethi, A.K.; Yadavalli, G.K.; Donskey, C.J. Reduction of Clostridium Difficile and vancomycin-resistant Enterococcus contamination of environmental surfaces after an intervention to improve cleaning methods. BMC Infect. Dis., 2007, 7, 61.
64. Hayden, M.K.; Bonten, M.J.; Blom, D.W.; Lyle, E.A.; van de Vijver, D.A.; Weinstein, R.A. Reduction in acquisition of vancomycin-resistant enterococcus after enforcement of routine environmental cleaning measures. Clin. Infect. Dis., 2006, 42(11), 1552-1560.
65. Doidge, M.; Allworth, A.M.; Woods, M.; Marshall, P.; Terry, M.; O'Brien, K.; Goh, H.M.; George, N.; Nimmo, G.R.; Schembri, M.A.; Lipman, J.; Paterson, D.L. Control of an Outbreak of Carbapenem-Resistant Acinetobacter baumannii in Australia after Introduction of Environmental Cleaning with a Commercial Oxidizing Disinfectant. Infect. Control Hosp. Epidemiol., 2010, 31(4), 418-420.
66. Kollef, M.H. Broad-spectrum antimicrobials and the treatment of serious bacterial infections: getting it right up front. Clin. Infect. Dis., 2008, 47(Suppl 1), S3-13.
67. Safdar, N.; Maki, D.G. The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus, enterococcus, gram-negative bacilli, Clostridium difficile, and Candida. Ann. Intern. Med., 2002, 136(11), 834-844.
68. Dellit, T.H.; Owens, R.C.; McGowan, J.E., Jr.; Gerding, D.N.; Weinstein, R.A.; Burke, J.P.; Huskins, W.C.; Paterson, D.L.; Fishman, N.O.; Carpenter, C.F.; Brennan, P.J.; Billeter, M.; Hooton, T.M. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin. Infect. Dis., 2007, 44(2), 159-177.
69. Paterson, D.L. The role of antimicrobial management programs in optimizing antibiotic prescribing within hospitals. Clin. Infect. Dis., 2006, 42 (Suppl 2), S90-95.
70. Rahal, J.J.; Urban, C.; Horn, D.; Freeman, K.; Segal-Maurer, S.; Maurer, J.; Mariano, N.; Marks, S.; Burns, J.M.; Dominick, D.; Lim, M. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. JAMA, 1998, 280(14), 1233-1237.
71. Enne, V.I. Reducing antimicrobial resistance in the community by restricting prescribing: can it be done? J. Antimicrob. Chemother., 2010, 65(2), 179-182.
72. Paterson, D.L. Restrictive antibiotic policies are appropriate in intensive care units. Crit. Care Med., 2003, 31(1 Suppl), S25-28.
73. Stamey, T.A.; Bragonje, J. Resistance to nalidixic acid. A misconception due to underdosage. JAMA, 1976, 236(16), 1857-1860.
74. Blaser, J.; Stone, B.B.; Groner, M.C.; Zinner, S.H. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob. Agents Chemother., 1987, 31(7), 1054-1060.
75. Thorburn, C.E.; Edwards, D.I. The effect of pharmacokinetics on the bactericidal activity of ciprofloxacin and sparfloxacin against Streptococcus pneumoniae and the emergence of resistance. J. Antimicrob. Chemother., 2001, 48(1), 15-22.
76. Gumbo, T.; Louie, A.; Deziel, M.R.; Parsons, L.M.; Salfinger, M.; Drusano, G.L. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. J. Infect. Dis., 2004, 190(9), 1642-1651.
77. Daikos, G.L.; Jackson, G.G.; Lolans, V.T.; Livermore, D.M. Adaptive resistance to aminoglycoside antibiotics from firstexposure down-regulation. J. Infect. Dis., 1990, 162(2), 414-20.
78. Fantin, B.; Farinotti, R.; Thabaut, A.; Carbon, C. Conditions for the emergence of resistance to cefpirome and ceftazidime in experimental endocarditis due to Pseudomonas aeruginosa. J. Antimicrob. Chemother., 1994, 33(3), 563-569.
79. Tam, V.H.; Schilling, A.N.; Neshat, S.; Poole, K.; Melnick, D.A.; Coyle, E.A. Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa. Antimicrob. Agents Chemother., 2005, 49(12), 4920-4927.
80. Drusano, G.L. Impact of pharmacodynamic dosing of meropenem on emergence of resistance during treatment of ventilatorassociated pneumonia: A prospective clinical trial. In Interscience Conference of Antimicrobial Agents and Chemotherapy, Washington DC, 2005.
81. Chastre, J.; Wunderink, R.; Prokocimer, P.; Lee, M.; Kaniga, K.; Friedland, I. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit. Care Med., 2008, 36(4), 1089-1096.
82. Firsov, A.A.; Smirnova, M.V.; Lubenko, I.Y.; Vostrov, S.N.; Portnoy, Y.A.; Zinner, S.H. Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to daptomycin and vancomycin in an in vitro dynamic model. J. Antimicrob. Chemother., 2006, 58(6), 1185-1192.
83. Livermore, D.M. Linezolid in vitro: mechanism and antibacterial spectrum. J. Antimicrob. Chemother., 2003, 51(Suppl 2), 9-16.